Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$196.79−10.01 (-4.84%)
Close on Nov 18, 2026Market cap $78.57BP/E –Yield –
Moderna revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Moderna's revenue for the twelve months ending Jun 30, 2026 was $2.23B, down 27.6% year over year. For fiscal 2025 it was $1.94B, down 39.9% from the year before. The highest annual figure on record is $19.26B in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.94B | -39.9% |
| FY2024 | Dec 31, 2024 | $3.24B | -52.7% |
| FY2023 | Dec 31, 2023 | $6.85B | -64.4% |
| FY2022 | Dec 31, 2022 | $19.26B | +4.3% |
| FY2021 | Dec 31, 2021 | $18.47B | +2200.2% |
| FY2020 | Dec 31, 2020 | $803.00M | +1238.3% |
| FY2019 | Dec 31, 2019 | $60.00M | -55.6% |
| FY2018 | Dec 31, 2018 | $135.07M | -34.4% |
| FY2017 | Dec 31, 2017 | $205.83M | +89.9% |
| FY2016 | Dec 31, 2016 | $108.40M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $145.00M | +2.1% |
| Q1 FY2026 | Mar 31, 2026 | $389.00M | +260.2% |
| Q4 FY2025 | Dec 31, 2025 | $678.00M | -29.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.02B | -45.4% |
| Q2 FY2025 | Jun 30, 2025 | $142.00M | -41.1% |
| Q1 FY2025 | Mar 31, 2025 | $108.00M | -35.3% |
| Q4 FY2024 | Dec 31, 2024 | $966.00M | -65.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.86B | +1.7% |
| Q2 FY2024 | Jun 30, 2024 | $241.00M | -29.9% |
| Q1 FY2024 | Mar 31, 2024 | $167.00M | -91.0% |
| Q4 FY2023 | Dec 31, 2023 | $2.81B | -44.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.83B | -45.6% |
| Q2 FY2023 | Jun 30, 2023 | $344.00M | -92.8% |
| Q1 FY2023 | Mar 31, 2023 | $1.86B | -69.3% |
| Q4 FY2022 | Dec 31, 2022 | $5.08B | -29.5% |
| Q3 FY2022 | Sep 30, 2022 | $3.36B | -32.3% |
| Q2 FY2022 | Jun 30, 2022 | $4.75B | +9.1% |
| Q1 FY2022 | Mar 31, 2022 | $6.07B | +213.2% |
| Q4 FY2021 | Dec 31, 2021 | $7.21B | +1162.9% |
| Q3 FY2021 | Sep 30, 2021 | $4.97B | +3065.0% |
| Q2 FY2021 | Jun 30, 2021 | $4.35B | +6398.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.94B | +24112.5% |
| Q4 FY2020 | Dec 31, 2020 | $571.00M | +3962.6% |
| Q3 FY2020 | Sep 30, 2020 | $157.00M | +821.0% |
| Q2 FY2020 | Jun 30, 2020 | $67.00M | +412.1% |
| Q1 FY2020 | Mar 31, 2020 | $8.00M | -50.1% |
| Q4 FY2019 | Dec 31, 2019 | $14.06M | -60.3% |
| Q3 FY2019 | Sep 30, 2019 | $17.05M | -59.2% |
| Q2 FY2019 | Jun 30, 2019 | $13.08M | -54.7% |
| Q1 FY2019 | Mar 31, 2019 | $16.03M | -44.8% |
| Q4 FY2018 | Dec 31, 2018 | $35.42M | -61.5% |
| Q3 FY2018 | Sep 30, 2018 | $41.76M | -1.7% |
| Q2 FY2018 | Jun 30, 2018 | $28.85M | -29.8% |
| Q1 FY2018 | Mar 31, 2018 | $29.04M | -4.3% |
| Q4 FY2017 | Dec 31, 2017 | $91.90M | – |
| Q3 FY2017 | Sep 30, 2017 | $42.47M | – |
| Q2 FY2017 | Jun 30, 2017 | $41.12M | – |
| Q1 FY2017 | Mar 31, 2017 | $30.33M | – |
See a number that looks wrong?